Innovation-Driven Growth:
New AI-focused capabilities (e.g., AI Connectors built on Model Context Protocol) and a stated push to be an “AI platform for biotech R&D” signal ongoing product investment. Reported usage of Benchling AI across 500 biotech companies underscores adoption of these innovations.
Strategic Partnerships:
The January 2026 collaboration with Lilly’s TuneLab is positioned to bring proprietary models to scientists across Benchling’s customer base. Acqui-hires of ReSync Bio and Sphinx Bio in 2025 were used to accelerate the AI roadmap.
Strong Revenue Growth:
ARR was independently estimated around the low-$200 millions by mid-2024 with year-over-year increases, indicating continued top-line expansion. While the pace has moderated versus earlier years, the trajectory remains positive.
